Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway
Survivin is recognized as an attractive target in cancer therapy because of its selective overexpression in the majority of tumors. Upregulated expression of this protein correlates with increased tumor grade, recurrence risk and decreased cancer patients survival. In this study, we assessed the eff...
Saved in:
Published in | Journal of cellular biochemistry Vol. 105; no. 2; pp. 381 - 390 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.10.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Survivin is recognized as an attractive target in cancer therapy because of its selective overexpression in the majority of tumors. Upregulated expression of this protein correlates with increased tumor grade, recurrence risk and decreased cancer patients survival. In this study, we assessed the efficacy of two survivin‐specific small interfering RNA (siRNA) constructs to inhibit T47D human breast cancer cell growth. After siRNA transfection, T47D cells showed a significant reduction in proliferation and survival exhibiting clear signs of apoptosis. pSil_1 that targeted exon 1 exhibited a stronger inhibitory effect on cell growth, and increased cell apoptosis compared to pSil_30 that targeted exon 4. Cell apoptosis was found to be mediated by translocation of the mitochondrial apoptosis inducing factor (AIF), while no changes were observed in caspase‐3 activation and Bid cleavage. Thus, silencing survivin expression using siRNA strategies represents a suitable therapeutic approach to selectively modulate the survival and growth of human breast cancer cells. J. Cell. Biochem. 105: 381–390, 2008. © 2008 Wiley‐Liss, Inc. |
---|---|
Bibliography: | Universidad de Buenos Aires - No. M091 Comisión Honoraria de Lucha Contra el Cáncer (Uruguay) Gabriel A. Rabinovich and Viviana A. Rivarola jointly supervised this work. Diego O. Croci and Ingrid S. Cogno contributed equally to this work. ark:/67375/WNG-VK4G2S7R-W Cancer Research Institute Fundación Rene Baron ArticleID:JCB21836 Amigos del Instituto Leloir para la Lucha contra el Cáncer (AFULIC) istex:E483F34937B5F37450F142F08BA0FF8EFC6F8123 Fundación Sales Agencia Nacional de Promoción Científica y Tecnológica (PICTO) Programa de Cooperación Bilateral Argentina-Uruguay Agencia Nacional de Promoción Científica y Tecnológica - No. PICT 2003-05-13787 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0730-2312 1097-4644 |
DOI: | 10.1002/jcb.21836 |